U.K. tallies losses on pandemic vaccine

U.K. officials say they essentially lost more than £200 million ($308.9 million) buying up excess quantities of swine flu vaccine and antiviral meds. About a third of that loss occurred because unused vaccines weren't stored properly. And there's no secondary market for their surplus. "The worldwide surplus of swine flu vaccine means that there is no active market in which the department's excess pandemic flu inventory can be sold," health officials report. Story

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.